Home/Filings/4/0001415889-25-002004
4//SEC Filing

REED ELIZABETH E 4

Accession 0001415889-25-002004

CIK 0001438533other

Filed

Jan 22, 7:00 PM ET

Accepted

Jan 23, 8:37 PM ET

Size

5.3 KB

Accession

0001415889-25-002004

Insider Transaction Report

Form 4
Period: 2025-01-22
REED ELIZABETH E
Chief Legal Officer and GC
Transactions
  • Sale

    Common Stock

    2025-01-22$19.46/sh2,437$47,42476,933 total
Footnotes (2)
  • [F1]This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.
  • [F2]Includes 737 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on November 29, 2024.

Issuer

Travere Therapeutics, Inc.

CIK 0001438533

Entity typeother

Related Parties

1
  • filerCIK 0001283303

Filing Metadata

Form type
4
Filed
Jan 22, 7:00 PM ET
Accepted
Jan 23, 8:37 PM ET
Size
5.3 KB